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Elevated blood pressure (BP) and arterial stiffness increase cardiac afterload. Whether increased levels of ANP are associated with BP indices in hypertensive adults has not been established. Higher levels of natriuretic peptides have been reported in patients with essential hypertension than in normotensives, 1,2 but this observation has not been confirmed in other studies. 3, 4 In a large (n = 1,338) population-based study, Flickinger et al. 5 found no association between plasma levels of ANP and systolic blood pressure (SBP), diastolic blood pressure (DBP), or the presence of hypertension. However, in the Framingham Heart Study, higher levels of NT-ANP and NT-BNP were associated with higher SBP and lower DBP. 6 A potential explanation for these conflicting results could be that conventional assays measure the mature ANP peptide that has a low half life. ANP is derived from the cleavage of its precursor prohormone, which is significantly more stable in the circulation than the mature peptide. A midregional fragment of the precursor hormone (amino acids 53-90 of NT-proANP), called midregional pro-atrial natriuretic peptide (MR-proANP), may be relatively resistant to degradation by exoproteases, unlike epitopes in the N or C terminals of proANP used in previous immunoassays. 7, 8 Previous studies may, therefore, have underestimated the utility of ANP/ proANP as a biomarker.
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MR-proANP and Measures of Blood Pressure
We hypothesized that in adults with essential hypertension, plasma levels of MR-proANP would be associated with higher SBP, greater arterial stiffness, and severity of hypertension. We, therefore, examined the association of plasma levels of MR-proANP with SBP, pulse pressure, and hypertension severity in a biethnic cohort of adults with essential hypertension. We sought to determine whether any detected association was independent of confounding variables, particularly age, body mass index (BMI), and renal function.
Methods
The study was part of the Proteomic Markers of Arteriosclerosis Study, which is investigating the association of multiple markers in various etiologic pathway of vascular disease with several phenotypes of arteriosclerosis. 9, 10 Participants belonged to the Genetic Epidemiology Network of Arteriopathy (GENOA) Study, a multicenter, community-based study that aims to identify genetic variants influencing BP levels and the development of target organ damage due to hypertension. 11 Participants were enrolled if two or more members of a sibship had hypertension. The only exclusionary criterion at enrollment was the presence of a secondary cause of hypertension (such as documented renal artery stenosis or advanced renal insufficiency) in the index sibs. The sampling frame of the Genetic Epidemiology Network of Arteriopathy-Rochester cohort was the Mayo Clinic diagnostic index and medical record linkage system of the Rochester Epidemiology Project. It was used to identify non-Hispanic white residents of Olmsted County, Minnesota, with a diagnosis of essential hypertension made before age 60. The Jackson, Mississippi, cohort of the Atherosclerosis Risk in Communities Study, 12 which had originally been a probability sample of persons with driver's licenses, was used to ascertain African-American sibships. If the eligible proband had at least one sibling with hypertension, all available full biologic siblings of the index hypertensive including normotensive siblings were invited to participate in interviews, physical examinations, and phlebotomy. The study was approved by the Institutional Review Boards of the University of Mississippi Medical Center, Jackson, Mississippi, and Mayo Clinic, Rochester, Minnesota. Written informed consent was obtained from each participant. The present study included 1,914 participants (1,034 African Americans and 880 non-Hispanic whites) who had hypertension.
Height was measured by stadiometer, weight by electronic balance, and BMI was calculated as weight in kilograms divided by the square of height in meters. Diabetes was considered present if the participant was being treated with insulin or oral agents or had a fasting glucose level ≥126 mg/dl. "Ever" smoking was defined as having smoked >100 cigarettes. Information about the use of medications was obtained from the participants at the time of the study visit. Each prescription drug recorded at the study visit was assigned a code number corresponding to the first six digits of the Medi-Span Generic Product Identifier. 13 This number identifies pharmacologically equivalent drug products and was used to categorize agents with a similar therapeutic action. 13 BP-lowering medications were classified as diuretics, β-blockers, calcium-channel blockers, or renin-angiotensin-aldosterone system (RAAS) inhibitors.
Blood was drawn by venipuncture after an overnight fast. Serum total cholesterol and high-density lipoprotein (HDL) cholesterol were measured by standard enzymatic methods. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation as previously described. 14 Resting SBP and DBP were measured by random zero sphygmomanometer (Hawskley and Sons, London, UK) after participants had rested for at least 10 min in the supine position. Three measures at least 2 min apart were taken, and the average of the second and third measurements was used. The diagnosis of hypertension was established based on BP levels measured at the study visit (≥140/90 mm Hg) or a prior diagnosis of hypertension and current treatment with antihypertensive medications. Pulse pressure was calculated as the difference between SBP and DBP. We used a measure of hypertension severity that accounted for medication use. 15 The hypertension severity score was based on the number of antihypertensive medications and the BP as follows: number of hypertension medication classes a patient was taking + (DBP − 70)/30 + (SBP − 120)/60. 15 Plasma levels of MR-proANP. Plasma was collected at the time of blood sampling in plastic vials containing ethylenediaminetetraacetic acid. These were placed on ice and then centrifuged at 3,000g and frozen at −80 °C until assayed. MR-proANP was detected using a novel commercial sandwich immunoassay in the chemiluminescence-coated tube format (MR-proANP LIA, BRAHMS, Hennigsdorf/Berlin, Germany) as previously described. 8 Briefly, patient samples (1:40 dilution of 5 µl plasma in incubation buffer) or standards were added in duplicate to antibody-coated tubes (affinity purified sheep polyclonal antibodies directed against proANP peptide 73-90) and incubated for 30 min at room temperature. After washes with 1 ml washing buffer, 200 µl tracer was added, containing acridinium ester-labeled anti-proANP antibody (affinity purified sheep polyclonal antibodies directed against proANP peptide 53-72), followed by 30 min incubation at room temperature. Tubes were washed with 1 ml washing buffer, and detection was performed in a LB952T luminometer (Berthold, Bad Wildbad, Germany; 1 s detection time per sample). Relative light units of the chemiluminescence assay were expressed in pmol/l MR-proANP, as calculated from a calibration curve (4-1,800 pmol/l) that was included in every analytical run. The lower detection limit of the assay is 4.3 pmol/l and the functional sensitivity of the assay is 11 pmol/l MR-proANP. The interassay coefficient of variation within the range of plasma measurements was under 10% (8.0% coefficient of variation at 100 pmol/l; 6.5% coefficient of variation at 400 pmol/l). Participants (n = 13) with MR-proANP levels >400 pmol/l were excluded from the analyses as such levels may be due to left ventricular dysfunction.
Statistical methods. Statistical analyses were carried out using SAS v 9.1 (SAS Institute, Cary, NC) software package. Because articles
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of the presence of sibships in the sample, regression analyses were performed using generalized estimating equations. 16 Continuous data were summarized as either mean ± s.d. or median and quartiles, and categorical data were expressed as percentages. Because of significant differences in age and the proportion of women between the two ethnic groups, participant characteristics were compared after adjustment for age and sex. The P value for the trends across quartiles of plasma MR-proANP levels was assessed using analysis of variance and Kruskal Wallis test for continuous variables and likelihood ratio tests for categorical data. Plasma MR-proANP and serum creatinine were log transformed to reduce skewness. In each ethnic group, we constructed multiple regression models that included age, sex, BMI, total and HDL cholesterol, smoking history, diabetes, previous history of myocardial infarction (MI) or stroke, medication (BP-lowering, statin, and aspirin) use, eGFR, and MR-proANP and then performed backward elimination to identify the set of variables independently associated with BP measures. The mean BP indices in each quartile of plasma levels of MR-proANP were estimated using least squares means. We also checked for interactions between conventional risk factors and MR-proANP in the prediction of BP indices and incorporated interactions significant at P < 0.01 in the models. In addition, to evaluate whether any association between MR-proANP levels and BP indices was modified by ethnicity, we performed analyses including all participants, using ethnicity as a covariate in the regression models. A two-sided P value of <0.05 was deemed statistically significant.
results
African Americans were older, and there were a greater proportion of women in both African American and non-Hispanic white cohorts ( Table 1) . After adjustment for age and sex, African Americans had a higher prevalence of diabetes, lower use of statins, and higher eGFR than their non-Hispanic white counterparts. Although SBP, pulse pressure, and hypertension severity were greater in African Americans, MR-proANP levels were similar in both ethnic groups ( Table 1) .
For each ethnic group, participant characteristics in quartiles of MR-proANP levels are presented in Table 2 . Older age, lower BMI, higher HDL cholesterol, greater SBP, pulse pressure, hypertension severity (Figure 1a) , lower eGFR, previous history of MI or stroke, and use of β-blockers were each significantly associated with higher plasma MR-proANP levels in African Americans. After adjustment for age and sex, African Americans in the highest quartile of MR-proANP levels had significantly greater SBP (10.1 mm Hg increase, P < 0.0001), pulse pressure (8.4 mm Hg increase, P < 0.0001), and hypertension severity (0.53 unit increase, P < 0.0001) than in those in the bottom quartile ( Table 3) . In separate multivariable linear regression models, after adjustment for age, sex, BMI, total and HDL cholesterol, eGFR, smoking history, diabetes, previous history of MI or stroke, and medication (β-blocker, statin, and aspirin) use, higher MR-proANP levels were significantly associated with greater SBP (P < 0.0001), pulse pressure (P < 0.0001), and hypertension severity (P = 0.0013). African Americans in the highest quartile of MR-proANP levels had significantly greater SBP (10.5 mm Hg increase, P < 0.0001), pulse pressure (9.0 mm Hg increase, P < 0.0001), and hypertension severity (0.42 unit increase, P = 0.0002) than in those in the bottom quartile ( Table 3) .
Similar findings were noted in non-Hispanic whites. Older age, female sex, higher HDL cholesterol, greater SBP, pulse pressure, hypertension severity (Figure 1b) , lower DBP, lower eGFR, previous history of MI or stroke, and use of β-blockers and aspirin were associated with higher plasma MR-proANP levels. After adjustment for age and sex, non-Hispanic whites in the highest quartiles of MR-proANP levels had significantly greater SBP (4.7 mm Hg increase, P = 0.012), pulse pressure (6.6 mm Hg increase, P < 0.0001), and hypertension severity (0.30 unit increase, P = 0.002) than in those in the bottom quartile ( Table 3) . In separate multivariable linear regression 
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Continuous variables are presented as means ± standard deviation or median and interquartile range, whereas categorical variables are presented as counts and percentages. P values are for ethnic differences after adjustment for age and sex. BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; MI, myocardial infarction; MR-proANP, midregional pro-atrial natriuretic peptide; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure.
articles MR-proANP and Measures of Blood Pressure models, after adjustment for age, sex, BMI, total and HDL cholesterol, eGFR, smoking history, diabetes, previous history of MI or stroke, and medication (β-blocker, statin, and aspirin) use, higher MR-proANP levels were significantly associated with greater SBP (P = 0.013), pulse pressure (P = 0.0006), and hypertension severity (P = 0.028) ( Table 3) . Non-Hispanic whites in the highest quartiles of MR-proANP levels had significantly greater SBP (4.6 mm Hg increase, P = 0.006), pulse pressure (6.2 mm Hg increase, P < 0.0001), and hypertension severity (0.26 unit increase, P = 0.005) than in those in the bottom quartile ( Table 3) . The regression coefficients for the association between MR-proANP and BP indices were greater in African Americans. However, in the pooled sample, after adjustment for potentially confounding variables, we did not find a statistically significant interaction between ethnicity and MR-proANP levels in predicting SBP (P = 0.14), pulse pressure (P = 0.31), or hypertension severity (P = 0.89) (analysis not shown).
discussion
To the best of our knowledge, this study is the first to report an independent association of MR-proANP, a stable fragment (18) 29 (13) 50 (23) 0.090
History of MI/stroke, n (%) 19 (7) 31 (12) 27 (10) 61 (24) <0.0001 27 (12) 21 (10) 27 (12) 47 (21) 0.0037
Statin, n (%) 55 (21) 52 (20) 46 (18) 71 (28) 
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of the N-terminal part of pro-atrial natriuretic peptide, with SBP, pulse pressure, and severity of hypertension in adults with hypertension. Our findings suggest that plasma MR-proANP may be a marker of arterial stiffness and severity of hypertension in adults with hypertension. These associations remained significant even after adjustment for age, sex, conventional risk factors, eGFR, and medication use and were present in both African Americans and non-Hispanic whites. The natriuretic peptides have several physiologic roles, including regulation of BP, salt and water excretion, cell proliferation, and vasodilator tone. 17, 18 The natriuretic peptide axis is influenced by multiple pathophysiological signals, including left and right ventricular dysfunction, cardiac hypertrophy, elevated intracardiac filling pressure, diastolic dysfunction, valvular disease, cardiac ischemia, and renal disease. 19, 20 Knocking out the ANP gene in mice results in salt sensitive hypertension and significant cardiac enlargement, 21 whereas overexpression of the gene in transgenic mice results in lower BP. 22 Moreover, administration of recombinant ANP lowers BP levels in humans and in animal models. 23, 24 Chronic hypertension eventually leads to volume and pressure overload and ultimately left ventricular hypertrophy; left ventricular compliance decreases, leading to increased atrial work and atrial stretch, a major stimulus for ANP release. In separate analyses, we found a significant association between MR-proANP levels and left ventricular mass in African Americans. 25 The association between MR-proANP levels and BP indices may reflect a feedback mechanism to increase sodium excretion and lower BP in the presence of hypertension. Patients with more severe hypertension therefore have higher ANP levels, and ANP levels may serve as a marker of elevated BP and increased left ventricular and atrial work in hypertensive adults. Elevated levels of MR-proANP (in the absence of heart failure) may indicate a need for intensive pharmacologic therapy to reduce BP.
Levels of MR-proANP were significantly associated with pulse pressure in both ethnic groups, highlighting that arterial stiffness increases ANP secretion likely by increasing left ventricular and atrial stretch. The association of MR-proANP with pulse pressure was predominantly due to its association with increased SBP in African Americans. In non-Hispanic whites, higher MR-proANP was associated with higher SBP as well as a lower DBP. In a report from Framingham Heart Study (n = 1,962, 43% hypertensive), NT-proANP was associated with carotid pulse pressure in men but not in women. 26 In contrast, in this study, we did not find any interaction between MR-proANP and sex in the prediction of pulse pressure.
In investigating the association between MR-proANP and BP indices, we considered the confounding effect of several variables, most importantly, age, sex, BMI, eGFR, and medication use. Consistent with previous reports, age was significantly, independently associated with higher MR-proANP levels in both ethnic groups. 6, 27 This could be due to increased myocardial fibrosis, greater arterial stiffness, and a reduction in renal and nonrenal clearance mechanisms in the elderly. An inverse relationship between NT-proANP and BMI was described in the Framingham Heart Study 28 and by Khush et al. 29 We noted a weak inverse association with BMI that was no longer significant after adjustment for age (analyses not shown).
Women had higher levels of MR-proANP than men, although in African Americans the difference was significant only after adjustment for other variables. The associations observed in our study were present in both men and women (analyses not shown). Lower eGFR was significantly associated with higher MR-proANP levels, a finding also noted by Codognotto et al. 30 , indicating that renal clearance is an important determinant of plasma levels of ANP. β-blocker use was significantly associated with higher MR-proANP levels independent of heart rate and other confounding variables.
Luchner et al. 31 also reported a similar finding in a population-based sample (n = 672). The mechanism underlying this association remains to be delineated. Hypertension is highly prevalent in African Americans and tends to be more severe and more often associated with target organ damage compared to non-Hispanic whites. 32 The attributable risk of death due to hypertension in African Americans is ~30%, double that in non-Hispanic whites. 32 Although hypertension was more severe in African Americans than in non-Hispanic whites in this study, MR-proANP levels were similar in the two ethnic groups after adjustment for age and sex, or even after adjustment for other conventional risk factors and medications (analysis not shown). This result implies that either African Americans have lower baseline level of ANP or a blunted neurohumoral reflex compared to nonHispanic whites. Whether this contributes to the susceptibility of African Americans to hypertension and target organ damage mediated by hypertension merits further investigation.
A strength of the present study is the inclusion of a large biethnic cohort of adults with hypertension and the use of uniform protocols, including questionnaires, anthropometric, and laboratory measurements. In addition, plasma levels of NT-proANP were measured using a novel immunoassay covering midregional epitopes, allowing a more reliable assessment of ANP release. Limitations of this study include its cross-sectional nature. The majority of patients in this study were on BP-lowering medications at the time of measuring BP indices and MR-proANP levels, and this may have influenced cross-sectional associations noted in our study. However, this would tend to lessen the ability to find associations between ANP and BP indices. The hypertension severity score we used needs to be validated in other studies.
Hypertension affects ≥65 million adult Americans and is associated with subclinical target organ damage, a major cause of morbidity and mortality in hypertension. MR-proANP is a newly described fragment of the N-terminal part of pro-atrial natriuretic peptide that is relatively resistant to degradation by exoproteases and is significantly more stable in the circulation than the mature peptide. Our results suggest that plasma levels of MR-proANP are independently associated with greater SBP, pulse pressure, and hypertension severity in adults with hypertension. The fact that MR-proANP was associated with BP indices independent of age, sex, eGFR, conventional risk factors, and medication use indicates the potential use of MR-proANP as a marker of arterial stiffness and severity of hypertension in adults with hypertension. In a 12-week double blind, randomized clinical trial, a greater reduction in central and peripheral pulse pressure was reported in hypertensive subjects treated with omapatrilat, a vasopeptidase inhibitor that inhibits both angiotensin converting enzyme and neutral endopeptidase (an enzyme that inactivates several vasodilatory peptides, including the natriuretic peptides), compared to enalapril, suggesting a potential role for pharmacological modulation of natriuretic peptides in the treatment of hypertension. 33 Further investigation is needed to assess the utility of measurement of plasma MR-proANP for early detection of target organ damage in adults with hypertension.
